• HOME |
  • SITE MAP |
  • CONTACT |
  • KOREAN
Product Search
  • Introduction
  • R&D
  • Products
  • Help Desk
since 1897 R&D visual

R&D

  • About R&D
  • Research Achievements
  • Organization of research institute
  • Key Research Area
  • R&D Pipeline
  • Technical Innovation Network
  • Global Dong Wha

R&D Pipeline

Innovative new drugs

Project Indication Hit Lead Candidate Preclinical Clinical

DW2008

Natural compound with bronchial inflammation suppression and expansion effect

 Asthma

DW1023

Anti-tumor effect confirmed in lymphoma animal model

 Oncology

DW1024

Drug that inhibits inflammatory action and modulates immune response

 Immunology

DW1025

Novel target drug for moderate to severe asthma

 Asthma

DW1030

Novel target drug that promotes mitochondrial function in muscle

 Sarcopenia

Incrementally modified drugs(IMD)

Project Indication Discovery Preclinical Clinical Approval

DW6012

Fixed-dose combination of two diabetes drugs with different MoA

 Diabetes

DW6013

Fixed-dose combination drug that combined two diabetes drugs and improved an immediate-release into a sustained-release

 Diabetes

DW6014

Fixed-dose combination drug that combined two diabetes drugs and improved an immediate-release into a sustained-release

 Diabetes

DW6015

Fixed-dose combination drug that combined two diabetes drugs and improved an immediate-release into a sustained-release

 Diabetes

Functional ingredients

Project Indication Discovery Preclinical Clinical Approval

DW2009

First functional probiotics for cognitive function improvement

 Cognitive function improvement

DW2012

Probiotics for muscle strength improvement

 Muscle strength improvement
Go to TOP

6~8F, FastFive Tower, 24, Namdaemun-ro 9-gil, Jung-gu, Seoul, 04522, KOREA

Coptright(c) Dong Wha PHARM.CO.,LTD. All Rights Reserved.